Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine
- PMID: 24141084
- DOI: 10.1016/j.neulet.2013.09.059
Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine
Abstract
Brain-derived neurotrophic factor (BDNF) regulates the survival and growth of neurons, and influences synaptic efficiency and plasticity. Peripheral BDNF levels in patients with schizophrenia have been widely reported in the literature. However, it is still controversial whether peripheral levels of BDNF are altered in patients with schizophrenia. The peripheral BDNF levels previously reported in patients with schizophrenia were total BDNF (proBDNF and mature BDNF) as it was unable to specifically measure mature BDNF due to limited BDNF antibody specificity. In this study, we examined whether peripheral levels of mature BDNF were altered in patients with treatment-resistant schizophrenia. Matrix metalloproteinase-9 (MMP-9) levels were also measured, as MMP-9 plays a role in the conversion of proBDNF to mature BDNF. Twenty-two patients with treatment-resistant schizophrenia treated with clozapine and 22 age- and sex-matched healthy controls were enrolled. The plasma levels of mature BDNF and MMP-9 were measured using ELISA kits. No significant difference was observed for mature BDNF however, MMP-9 was significantly increased in patients with schizophrenia. The significant correlation was observed between mature BDNF and MMP-9 plasma levels. Neither mature BDNF nor MMP-9 plasma levels were associated clinical variables. Our results do not support the view that peripheral BDNF levels are associated with schizophrenia. MMP-9 may play a role in the pathophysiology of schizophrenia and serve as a biomarker for schizophrenia.
Keywords: BDNF; Brain-derived neurotrophic factor (BDNF); Clozapine; DSM-IV; MDD; MMP-9; Matrix metalloproteinase-9 (MMP-9); PANSS; Treatment-resistant schizophrenia; brain-derived neurotrophic factor; diagnostic and statistical manual of mental disorders, fourth edition; major depressive disorder; matrix metalloproteinase-9; positive and negative syndrome scale.
Copyright © 2013 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.
Similar articles
-
Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder.PLoS One. 2012;7(8):e42676. doi: 10.1371/journal.pone.0042676. Epub 2012 Aug 3. PLoS One. 2012. PMID: 22880079 Free PMC article.
-
A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia.Psychiatry Res. 2014 Feb 28;215(2):268-73. doi: 10.1016/j.psychres.2013.12.009. Epub 2013 Dec 14. Psychiatry Res. 2014. PMID: 24377440
-
Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment.Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):709-13. doi: 10.1016/j.pnpbp.2004.05.008. Prog Neuropsychopharmacol Biol Psychiatry. 2004. PMID: 15276697 Clinical Trial.
-
Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: a review.J Biol Regul Homeost Agents. 2012 Jul-Sep;26(3):347-56. J Biol Regul Homeost Agents. 2012. PMID: 23034254 Review.
-
Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions.Psychiatry Clin Neurosci. 2010 Aug;64(4):341-57. doi: 10.1111/j.1440-1819.2010.02113.x. Psychiatry Clin Neurosci. 2010. PMID: 20653908 Review.
Cited by
-
Matrix metalloproteinase 9 (MMP-9) activity, hippocampal extracellular free water, and cognitive deficits are associated with each other in early phase psychosis.Neuropsychopharmacology. 2024 Mar 2. doi: 10.1038/s41386-024-01814-5. Online ahead of print. Neuropsychopharmacology. 2024. PMID: 38431757
-
Behavioral and transcriptional effects of repeated electroconvulsive seizures in the neonatal MK-801-treated rat model of schizophrenia.Psychopharmacology (Berl). 2024 Apr;241(4):817-832. doi: 10.1007/s00213-023-06511-7. Epub 2023 Dec 11. Psychopharmacology (Berl). 2024. PMID: 38081977
-
Levels of Matrix Metalloproteinase 9 Are Elevated in Persons With Schizophrenia or Bipolar Disorder: The Role of Modifiable Factors.Biol Psychiatry Glob Open Sci. 2023 Feb 24;3(4):766-772. doi: 10.1016/j.bpsgos.2023.02.007. eCollection 2023 Oct. Biol Psychiatry Glob Open Sci. 2023. PMID: 37881562 Free PMC article.
-
Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy.Indian J Psychiatry. 2023 Jun;65(6):694-697. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_320_22. Epub 2023 Jun 19. Indian J Psychiatry. 2023. PMID: 37485411 Free PMC article.
-
Characterization of early psychosis patients carrying a genetic vulnerability to redox dysregulation: a computational analysis of mechanism-based gene expression profile in fibroblasts.Mol Psychiatry. 2023 May;28(5):1983-1994. doi: 10.1038/s41380-023-02034-x. Epub 2023 Mar 31. Mol Psychiatry. 2023. PMID: 37002404 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
